Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an 8-K current report with the SEC on June 12, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Theresa M. Heggie, Amy E. McKee, and Jon P. Stonehouse elected as directors.
BIOCRYST PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Theresa M. Heggie, Amy E. McKee, and Jon P. Stonehouse elected as directors
- Director support ranged from 94.7% to 97.3% of votes cast, excluding broker non-votes
- Ernst & Young ratified as 2026 independent auditor, with 96.5% approval
- Executive compensation advisory vote approved with 68.9% support, signaling shareholder backing
- Incentive Plan Proposal approved with 65.4% support, authorizing continued equity-based compensation flexibility
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Annual meeting held June 11, 2026, with four proposals submitted to shareholders
- Three directors up for election through the 2029 annual meeting
- Ernst & Young LLP auditor appointment submitted for 2026 ratification
- Advisory executive-compensation vote and Incentive Plan Proposal also presented for approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOCRYST PHARMACEUTICALS INC 8-K filings
Get the next BCRX 8-K as it lands
Follow BCRX for push alerts, or ask the research agent what this filing means.